Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

Authors: Alan J. Garber, Robert R. Henry, Robert E. Ratner, Pedro Alberto García-Hernández, Hiromi Rodriguez-Pattzi, Israel Olvera-Alvarez, Paula M. Hale, Milan Zdravkovic, Bruce W. Bode - The Lancet 2008 cited by 1,053